Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Fulminant Acanthamoeba Encephalitis Diagnosed By Cell-Free DNA in a Renal Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same author

Qualified prediction system for allograft failure in real world settings: extended validation study.

BMJ medicine·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

A New Costimulatory Blockage Agent in the Pipeline.

Transplantation·2026
Same author

The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Awareness and outreach.

Nature clinical practice. Nephrology·2020
Same journal

Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms?

Nature clinical practice. Nephrology·2009
Same journal

Looking into the crystal ball: kidney transplantation in 2025.

Nature clinical practice. Nephrology·2009
Same journal

Depth of inflammation in Crohn's disease.

Nature clinical practice. Nephrology·2009
Same journal

Comment on "Home fingerprick sampling for immunosuppressant drug monitoring in pediatric renal transplant recipients".

Nature clinical practice. Nephrology·2009
Same journal

Skin problems in chronic kidney disease.

Nature clinical practice. Nephrology·2009
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Immunosuppression minimization protocols: how should they be monitored?

Enver Akalin1

  • 1Kidney and Pancreas Transplantation, Mount Sinai School of Medicine,New York, NY10029, USA. enver.akalin@mountsinai.org

Nature Clinical Practice. Nephrology
|August 6, 2008
PubMed
Summary
This summary is machine-generated.

Minimizing immunosuppression with alemtuzumab and tacrolimus in kidney transplant recipients may increase rejection risk and donor-specific antibodies (DSAs). Careful patient selection and close monitoring are crucial for this protocol.

More Related Videos

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: Jul 3, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

  • Nephrology
  • Transplantation Immunology

Background:

  • This study examines a protocol involving alemtuzumab induction and spaced weaning of tacrolimus monotherapy in renal allograft recipients.
  • The goal was to minimize immunosuppression while maintaining graft function.

Discussion:

  • While 44% achieved excellent graft survival without acute rejection or DSAs, 20% experienced acute rejection and 15% developed DSAs during immunosuppression tapering.
  • Graft survival was lower in patients who did not undergo weaning (63%) compared to those who experienced rejection (78%).

Key Insights:

  • Alemtuzumab induction with tacrolimus monotherapy and spaced weaning may elevate the risk of acute rejection and donor-specific antibody development.
  • Careful patient selection and vigilant monitoring for DSAs are essential for this immunosuppressive strategy.

Outlook:

  • Long-term controlled trials incorporating protocol biopsies are necessary to validate these findings and establish definitive conclusions.
  • Further research is needed to optimize immunosuppression minimization protocols for renal transplantation.